[Drugs news]

Arch Pediatr. 2015 Nov;22(11):1200-6. doi: 10.1016/j.arcped.2015.08.001. Epub 2015 Sep 15.

[Article in French]

Authors

C Lengellé¹, T Bejan-Angoulvant¹, F Beau-Salinas¹, A P Jonville-Béra²

Affiliations

¹ Département de pharmacologie, hôpital Bretonneau, CHRU de Tours, 2, boulevard Tonnellé, 37044 Tours cedex 9, France.
² Département de pharmacologie, hôpital Bretonneau, CHRU de Tours, 2, boulevard Tonnellé, 37044 Tours cedex 9, France. Electronic address: jonville-bera@chu-tours.fr.

PMID: 26385645
DOI: 10.1016/j.arcped.2015.08.001

No abstract available

Publication types

Comment

MeSH terms

Adrenergic beta-Antagonists / therapeutic use*
Angiotensin II Type 1 Receptor Blockers / therapeutic use*
Anti-Obesity Agents / adverse effects*
Anticonvulsants / adverse effects*
Aorta / drug effects*
Aortic Aneurysm / prevention & control*
Atenolol / therapeutic use*
Cleft Palate / chemically induced*
Female
Fructose / analogs & derivatives*
Hemangioma / congenital*
Hemangioma / epidemiology*
Humans
Losartan / therapeutic use*
Male
Marfan Syndrome / drug therapy*
Pregnancy
Prenatal Exposure Delayed Effects*
Skin Neoplasms / congenital*
Skin Neoplasms / epidemiology*

Substances

Adrenergic beta-Antagonists
Angiotensin II Type 1 Receptor Blockers
Anti-Obesity Agents
Anticonvulsants
Fructose
Atenolol
Losartan